Effect of Nepafenac Eye Drops on Pain Associated With Pterygium Surgery

Özçimen, Muammer; Sakarya, Yaşar; Göktaş, Sertan; Sakarya, Rabia; Yener, Halil İbrahim; Bukus, Abdulkadir; Demir, Lütfi Saltuk

doi:10.1097/icl.0000000000000107

Cited by 10 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[57][58][59][60] Pain Control Bhikoo et al 61 supported the use of 2 mL of intraoperative subtenon bupivacaine 0.5% toward the end of surgery to improve postoperative comfort by reducing pain and irritation. Ozcimen et al 62 determined that the use of topical nepafenac 0.1% every 8 hours for 3 days postoperatively significantly reduces postoper-ative pain. Goktas et al 63 suggests topical cyclopentolate 1% 3 times daily for 3 days postoperatively in addition to artificial tears also significantly lowers postoperative pain in comparison with artificial tears alone.…”

Section: Bandage Contact Lens Versus Patchingmentioning

confidence: 99%

Surgical Techniques and Adjuvants for the Management of Pterygium

Patel

Rhee

2021

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

To provide an updated review of surgical techniques and adjuvants for the management of pterygium. Methods: A literature search was conducted in PubMed for studies published since January 2011. "Pterygium surgery" and the MeSH term "Pterygium/surgery" was used. The results were filtered for randomized controlled trials in English, yielding 60 citations. Results: One study compared topical anesthetic agents. One study compared methods of corneal polishing of the corneoscleral bed after pterygium excision. Numerous studies evaluated the use of conjunctival autograft versus amniotic membrane, superior versus inferior conjunctival autograft, and conjunctival versus limbal-conjunctival autograft. Many studies evaluated graft fixation methods. Several studies evaluated the adjuvant use of mitomycin C, 5-fluorouracil, and bevacizumab. A few studies evaluated the adjuvant use of steroids. Eleven studies evaluated various methods of postoperative management. Conclusions: Current evidence supports pterygium excision with conjunctival autograft fixation using fibrin glue, followed by patching until the first postoperative visit. Surgical adjuvants and postoperative use of artificial tears and topical cyclosporine 0.05% may further reduce recurrence. Postoperative use of topical steroids is highly variable because there is no consensus regarding the optimal dose, frequency, and duration of treatment.

show abstract

Section: Bandage Contact Lens Versus Patchingmentioning

confidence: 99%

Surgical Techniques and Adjuvants for the Management of Pterygium

Patel

Rhee

2021

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

show abstract

“…It has been observed that nepafenac 0.1% eye drops administered thrice a day for 3 days (in association with postoperative therapy with topical ciprofloxacin, fluorometholone, and artificial tears) provided a significant pain reduction when compared with placebo after pterygium excision with autologous conjunctival graft. 166 An alternative treatment for rapid corneal epithelial healing and pain reduction after pterygium surgery is represented by autologous serum eye drops, which led to favorable results, as reported in a study by Sul et al 167 However, the evidence of autologous serum eye drops in pterygium surgery is currently limited. In addition, systemic analgesic drugs should be considered in the management of postoperative pain, especially if intense or persistent despite adequate topical treatment.…”

Section: Clinical Perspectivesmentioning

confidence: 99%

How to minimize pterygium recurrence rates: clinical perspectives

Nuzzi¹,

Tridico²

2018

OPTH

View full text Add to dashboard Cite

The main treatment for pterygium is surgical removal. However, pterygium surgery is concerned with high rates of postoperative recurrence. Predicting factors of recurrence are not fully understood, yet, but they probably depend on a multitude of patient-related, clinical, and/or surgical factors. Several adjuvant treatments have been proposed to reduce postoperative pterygium recurrence, including different antimetabolites, antiangiogenetic factors, and radiation therapy. The purpose of this review is to collect the current evidence regarding application and limits of different therapeutic approaches for preventing postoperative recurrence of pterygium, giving insights and perspectives for better management of this disease. In the light of the current evidence, pterygium surgery cannot disregard wound coverage with conjunctival autografting or rotational flap combined with adjuvant treatments. The rotational flap technique is associated with shorter surgical time rates and prevents graft displacement and necrosis, given its vascular pedicle. Amniotic membrane may still be reserved in case of great conjunctival defects or insufficient conjunctiva. Repeated subconjunctival antivascular endothelial growth factor injections can be considered as an effective and safe adjuvant treatment. Moreover, management of postoperative pain is crucial. Innovative treatment strategies will probably target different molecular pathways, considering recent findings regarding pterygium pathogenesis, to improve better understanding and develop universally shared guidelines. Great importance shall be dedicated to the identification of novel molecular biomarkers and favoring factors of recurrence, in order to achieve a customized surgical treatment for each patient and obtain maximal reduction of postoperative recurrence.

show abstract

“…2014), ocular discomfort after vitreous injections (Ulrich 2014) and postoperative pain associated with pterygium surgery (Ozcimen et al. 2015). However, we did not find published studies describing the frequency of nepafenac use or dispensing for the approved indication or other conditions in routine health care, as we did in this study.…”

Section: Discussionmentioning

confidence: 99%

Ophthalmic nepafenac use in the Netherlands and Denmark

Margulis¹,

Houben

Hallas

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac.MethodsWe identified users in the PHARMO Database Network (the Netherlands, 2008–2013) and the Danish national health registers (Denmark, 1994–2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes.ResultsIn the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery. Of 2266 episodes in adult non‐diabetic patients with cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days). Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to two bottles dispensed (≤60 days).Denmark had 60 403 nepafenac users (mean age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract surgery). Of 26 649 nepafenac episodes in adult non‐diabetic patients with cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult diabetic patients with cataract surgery, 99.8% had up to two bottles dispensed.Use patterns of nepafenac, ketorolac and diclofenac were roughly similar in the Netherlands, but not in Denmark.ConclusionLess than half of therapy episodes were related to cataract surgery; around 90% of episodes with surgery were within the approved duration. Underrecording of ophthalmic conditions and procedures was a challenge in this study.

show abstract

Effect of Nepafenac Eye Drops on Pain Associated With Pterygium Surgery

Abstract: Treatment with nepafenac ophthalmic suspension 0.1% significantly reduced postoperative pain compared with placebo after pterygium surgery.

Cited by 10 publications

References 18 publications

Surgical Techniques and Adjuvants for the Management of Pterygium

Surgical Techniques and Adjuvants for the Management of Pterygium

How to minimize pterygium recurrence rates: clinical perspectives

Ophthalmic nepafenac use in the Netherlands and Denmark

Contact Info

Product

Resources

About